Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert Smit

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME studyDenis Moro-Sibilot, Egbert Smit, Javier de Castro Carpeño, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2023
Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitorsFariba Tohidinezhad, Dennis Bontempi, Zhen Zhang, et al.
Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.
Lung Cancer (Amsterdam, Netherlands)|March 10, 2015
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational studyDenis Moro-Sibilot, Egbert Smit, Javier de Castro Carpeño, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshopRobert Pirker, Felix J F Herth, Keith M Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2003
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2018
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 StudyDirk De Ruysscher, Anne-Marie C Dingemans, John Praag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2023
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung CancerMasahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.
Cancers|December 9, 2023
<sup>89</sup>Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy OrgansIris H C Miedema, Jessica E Wijngaarden, Johanna E E Pouw, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME studyDenis Moro-Sibilot, Egbert Smit, Javier de Castro Carpeño, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2023
Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitorsFariba Tohidinezhad, Dennis Bontempi, Zhen Zhang, et al.
Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.
Lung Cancer (Amsterdam, Netherlands)|March 10, 2015
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational studyDenis Moro-Sibilot, Egbert Smit, Javier de Castro Carpeño, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshopRobert Pirker, Felix J F Herth, Keith M Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2003
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2018
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 StudyDirk De Ruysscher, Anne-Marie C Dingemans, John Praag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2023
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung CancerMasahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.
Cancers|December 9, 2023
<sup>89</sup>Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy OrgansIris H C Miedema, Jessica E Wijngaarden, Johanna E E Pouw, et al.
Pageof 5